Lidocaine infusion for the treatment of intractable trigeminal neuralgia: retrospective case series and systematic review - Takeaways - MDSpire

Lidocaine infusion for the treatment of intractable trigeminal neuralgia: retrospective case series and systematic review

  • By

  • Mohamed Wael Mohamed

  • Francis Irem-Oko

  • Asim Sheikh

  • Nicholas Phillips

  • Justin Mckinlay

  • Ian Anderson

  • September 29, 2025

  • 0 min

Share

  • 1

    Trigeminal neuralgia (TGN) is characterized by severe, unilateral facial pain, often lasting less than 2 minutes, and can be classified as classical or secondary.

  • 2

    First-line treatment for TGN typically involves carbamazepine, but 6-27% of patients may be refractory to standard pharmacological management.

  • 3

    Intravenous Lidocaine is proposed as a potential rescue therapy for patients with refractory TGN who are unsuitable for surgery or invasive treatments.

  • 4

    A retrospective case series at Leeds Teaching Hospitals evaluated the efficacy and safety of intravenous Lidocaine in 20 patients with refractory TGN.

  • 5

    The systematic review included studies assessing intravenous Lidocaine for TGN, focusing on pain outcomes and adhering to PRISMA guidelines.

Original Source(s)

Lidocaine infusion for the treatment of intractable trigeminal neuralgia: retrospective case series and systematic review

  • by Mohamed Wael Mohamed, Francis Irem-Oko, Asim Sheikh, Nicholas Phillips, Justin Mckinlay, Ian Anderson

  • September 29, 2025

Related Content

Advanced Brain Tumor Care, Close to Home

  • by

  • May 28, 2026

  • 2 min
Top 10 States for Physician-Owned Hospitals

These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.

The awakening effect of hyperbaric oxygen therapy combined with systematic auditory stimulation in comatose patients with craniocerebral injury and its influence on serum biomarkers